Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.

By G. Albers, H. Diener, L. Frison, M. Grind, Mark Nevinson, S. Partridge, J. Halperin, J. Horrow, S. Olsson, P. Petersen and 1 more. Journal of the American Medical Association (JAMA), 2005

730 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine, Nutrition and Dietetics

View Paper: https://www.semanticscholar.org/paper/206afbf8b2c6e180c9948f315420f095fc449c22

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Yan Yan
2. J. Halperin
3. Robert M. Califf
4. Harvey D. White
5. Cynthia Rudin
6. Berk Ustun
7. Rahul Wadke
8. Benjamin Letham

In Internal Medicine

1. J. Halperin
2. Cynthia Rudin
3. Berk Ustun
4. Rahul Wadke

In Nutrition and Dietetics

1. J. Halperin

Citations in the corpus

• Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. (2011, methodology): “The doses of warfarin and matching placebo tablets were adjusted based on these values.(12)”
• ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit (2006, neutral): “The results of the SPORTIF-V trial, in which treatment was administered in a double-blind manner, were similar to those of SPORTIF-III (438).”